Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history

Upendra Nagaich, Divya Sadhna

Departments of Pharmaceutics and Drug Regulatory Affairs, Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India

Abstract

There has been an increasing trend in the number of prescribed and over-the-counter drug recall over the last few years. The recall is usually due to company’s discovery, customer’s complaint or Food and Drug Administration (FDA) observation. The process of recall involves a planned specific course of action, which addresses the depth of recall, need for public warning, and the extent of effectiveness checks for the recall. The FDA review and/or recommend changes to the firm’s recall strategy, as appropriate. The critical recall information list includes the identity of the product; summary of the failure; amount of product produced in the distribution chain and direct account. Product recalls clash thousands of companies every year affecting: sales, testing customer relationships and disrupting supply chains. Drug recall is incubus for pharmaceutical companies. It impacts the reputation of the company. The reason for the recall can be divided into two categories: manufacturing affined and safety/efficacy affined. It is essential to follow all the guidelines related to drug development and manufacturing procedure so as to minimize drug recall.

Key words: Drug product recall, guidelines, process, recall information

INTRODUCTION

A drug recall is an instance to return to the maker a batch or an entire production run of a drug product, usually due to the detection of safety issues or drug product defect. When drug products are known to have potentially harmful effect on users due to their defective quality, safety or efficacy, they may be subjected to a recall and all related information’s are reported to the drug office [Table 1]. When Food and Drug Administration (FDA) found a violation of the laws, it issues a recall orders by which a firm remove or correct the market product. The agency would initiate legal action if the orders are not followed. There is a team responsible for coordinating all aspects related to product recall. The team is composed of endeavor to design, manufacture and sell safe and reliable products, the probability still a recall coordinator and members from the various functional areas.

Regard less a company’s best exists that dangerously defective drug product may reach the customers. These products may cause disasters, leading to adverse verdicts in drug product liability litigations. The quality management of complaints and drug product recalls are necessary to ensure the safety of customer. Recalls can be either unconstrained by the manufacturer, or rarely, injunction by FDA. Recalls vary in severity and in the action that must be contracted. It is possible that sometimes a drug company may recall only a specific batch or lot. However, there are certain other cases when all batches or lots of the drug experience recall from the market.

PURPOSE

This review article endows definitions, responsibility and procedure to initiate, review, classify, audit and terminate recall action. It also discusses the major drug recalls, reasons of recalls and strategies to overcome the recalls.

BACKGROUND

Recalls are a suitable alternative providence by the FDA for removing or correcting marketed consumer products, their labeling, and/or promotional literature that violate the laws administrated. Firms may initiate a recall following notification of a problem by FDA or a state agency, in response to a formal request by FDA, or as ordered by FDA. Manufacturers and/or distributors may also initiate a recall
at any time to fulfill their responsibility to protect the public health from drug products that show a risk of injury or gross spoof, or are otherwise defective. The FDA drug recall and other actions have been classified as the following five categories:\(^5\)

- Class I recall: Includes a health hazard situation where there is reasonable possibility that the use of the product will lead to serious, adverse health consequences or death.
- Class II recall: Includes a potential health hazard situation where there is a remote possibility of adverse health consequences from the use of the drug product.
- Class III recall: Includes a situation where the use of the drug product is not likely to cause adverse health outcome.
- Market withdrawal: When a product has a minor violation that would not be subject to FDA legal action “market withdrawal” occurs. The drug product is removed by the firm from the market or corrects the violation.
- Medical device safety alert: Released in circumstances where a medical device may present an unreasonable risk of substantial harm. These situations also are considered recalls in certain cases.

**THE RESPONSIBILITY OF FOOD AND DRUG ADMINISTRATION**

The FDA recall curriculum provides sufficient resources to process, to classify, and to publicize recalls on time. The responsibility of FDA is:\(^6\)

- To initiate the recall process, this includes two types of the voluntary recall: FDA requested, and FDA mandated.
- Determine that the action is a recall. The process of recall involves a planned specific course of action, which addresses:
  - The depth of recall,
  - Need for public warning, and
  - Extent of effectiveness checks for the recall.

The FDA review and/or recommend changes to the firm’s recall strategy, as appropriate.

| Drug recall | Drug withdrawal |
|-------------|----------------|
| A drug recall is an act taken by a firm to dislodge a drug product from the market that FDA considers to be in violation of the law. A drug may be recalled due to factors such as issues related to packaging, manufacturing, or contamination. | In seldom cases, FDA may need to reassess and change the drug product’s approval decision. A decision that a drug should no longer be marketed depends upon the nature and frequency of the adverse events and how the drug’s benefit and risk balance compares with treatment alternatives. When FDA recognizes that the drug’s benefits no longer outweigh its risks, the agency will ask the manufacturer to withdraw the drug.\(^6\) |

**SETTING UP FOR RECALL**

Food and Drug Administration deduces its recall regulations by specifying measures a “rational firm” can take to minimize disruption in the event of a recall.\(^7\)

1. FDA suggests setting and maintaining “current written contingency plan” for use in starting and affecting a recall in accordance with agency guidelines. The “written contingency plan” should be according to the standard operating procedure (SOP) that set forth what steps must be taken, in what series, and by whom, as soon as a potential recall situation has been recognized. These steps include:
   a. Evaluation of the information received,
   b. Identification of the nature and source of the problem,
   c. Determination of its breadth and depth,
   d. Evaluation of the potential health consequences,
   e. Decide whether to recall,
   f. Decide whether FDA should be notified,
   g. Develop a recall strategy,
   h. Communication of that strategy to FDA and work with the agency as appropriate to shape it,
   i. Implement the recall, and
   j. Conduct effective examination.

2. FDA instructs companies to sufficiently code regulated drug products in order to make corrective lot identification possible and to allow effective recall of all violative lots.

3. FDA encourages the maintenance of drug product distribution records essential to assist in the location of a recalled drug product. These records are kept for a period of time that exceeds the drug product’s shelf-life and expected use, and that is at least as long as the retention period specified in other exercisable regulations.

The responsibilities for personnel from essentially every division of the company, with prominent roles for Quality Assurance, Regulatory Affairs, Legal Counsel, and Senior Management...
are allotted. It usually helps to identify a core team that would manage the recall and assign key individuals decision-making authority at critical points during the process. It may also help to orchestrate a mock recall to test the effectiveness of the SOP. Finally, it would be prudent for the firm to review its insurance coverage for the recall event.

EXECUTION OF A RECALL

The recall execution involves the following steps:[8]

1. Determining the incumbent of recall
   - When a firm came to know about a potential recall situation, it needs to determine whether the product violates the standard guidelines and whether FDA would likely take legal action. The investigation is carried out so as to conclude whether drug recall is exigent or not.

2. Informing FDA
   - Not reporting a recall, however, can affect the firm’s rapport with the agency. Postulating the agency’s input in the planning process can also inhibit an enforcement action after the fact, if the agency concludes the recall lacked adequate depth or breadth. FDA actuates companies to endow notification of recalls, however, and it expects to be involved in the planning of any Class I recall. There may be certain cases where it is suitable not to notify the agency of a Class III recall, and some (fewer) situations where it is suitable not to notify of a Class II recall.

3. Evaluating the health hazards
   - A firm must evaluate the health hazard presented by the product when faced with a potential recall. An assessment of the health hazard should take into account:
     - Whether any disease or injuries have already occurred from the use of the product;
     - Whether any existing medical conditions could mask the risk from the product and whether products used to treat these conditions could contribute to (or lessen) the risk from the product;
     - The risk to various identifiable segments of the population, the relative frequency of use within each segment, and the risk to vulnerable groups like infants, children, elderly, pregnant women, and surgical patients;
     - The degree of seriousness of the hazard;
     - The likelihood of the occurrence of the hazard; and
     - Short-term and long-term consequences of the hazard.

It may be worth noting that whether users could be brought under closer medical supervision and whether any medical interventions (for example, medical monitoring) could lower the likelihood of harm.

4. Developing and implementing recall strategy
   - Each recall is uncouth and postulates its own recall strategy. A “recall strategy” is the planned specific curriculum of task to be taken in conducting a specific recall, which addresses the depth of the recall, necessity for public warnings, and the extent of effectiveness to scrutinize for the recall.
   - The strategy must customize the individual situation of the particular recall and must take into account among other relevant factors which includes:
     - The results of the health hazard evaluation;
     - The ease in identifying, isolating, and removing the violative product;
     - The degree to which the products deficiency is obvious to the consumer or user;
     - The amount of product remaining on the market; and
     - The need for continued availability of essential product.
   - The recall strategy should specify the requirement of “public warning” and if so whether that warning would issue through generalized or special news media.
   - The strategy should identify the methods which have to be used for “effective investigation checks,” which are intended to verify that recipients of the recalled drug product have received notice of the recall and have taken appropriate action in response.

5. Recall communication
   - A recalling firm is amenable for explicitly notifying each of its affect direct accounts about any recall it initiates. However, it should convey:
     - That the product is subject to a recall;
     - That further distribution or use of the product should stop immediately;
     - When appropriate, that the recipient should in turn notify the next party in the chain of distribution of the recall; and
     - What to do with the product.

6. Narration to FDA
   - A recalling firm is expected to provide periodic status reports regarding the progress of the recall to FDA. Unless otherwise set forth by the agency or inappropriate for the recall in question, a status report should have:
     - The number of recipients of the drug product notified of the recall and the method of notification;
     - The number of recipients responding to the recall and the number of drug products each recipient had in its possession upon receipt of the recall notification;
     - The number of recipients that did not respond;
     - The number of drug products returned pursuant to the recall;
     - The number and results of effectiveness checks conducted by the firm; and
     - The approximated completion date for the recall.

7. Terminating a recall[9]
   - A recall may be abolished when all reasonable endeavor have been made to remove or correct
the drug product in accordance with the recall strategy, and it is prudent to assume that the drug product subjected to the recall has been removed and proper disposition or correction has been made corresponding with the degree of hazard of the recalled drug product. Termination of a Class II or III recall does not require any prior approval by the center. In every case, written reportage that a recall is abolish will be issued by the appropriate District office to the recalling firm. FDA will not terminate a recall until the firm has brought the drug product into compliance or disposed of it in a conceded manner.

**RECALL ENTERPRISE SYSTEM**

The Recall Enterprise System (RES) is a database that involves the full array of communications amid the agency’s district offices and headquarters related to drug product recalls.[10] It allows FDA staff to perusal a recall event and sees the timeline of concerning agency activity.

The FDA recall personnel utilizes RES, which is an electronic data system used to submit, update, classify, and terminate recalls.

Districts don’t capture and track Market Withdrawals or Safety Alerts in the RES system.

Basic recall guidance and steps remain essentially same from those used prior to the initiation of RES. RES User Guides contain the detailed information required for the use of RES. Electronic copies of the guides are given to field and center recall coordinators.

**UNDERLAY OF DRUG RECALL**

A drug product recall may be:

- **Testament by a regulatory agency as an outcome of a violation of government act, standard or other mandatory regulations.**
- **Postulated to avoid potentially serious additional drug product liability claims or losses.**
- **Connoted by the analysis of field invigilating reports and feedback that may point to drug product tampering, near miss incidents, accidents or consumer complaints.**
- **Admonished by new acquaintance based on additional research and drug product testing.**
- **Required when characteristics of the drug product don’t meet the advertised claims for safety or effectiveness.**

### Table 2: Major drug recalls

| Tylenol[11] | Prescribed for | Maker | Financial damage | Recalled (year) |
|-------------|----------------|-------|------------------|-----------------|
| Tylenol     | Used for the relief of fever as well as aches and pains associated with many conditions | Johnson and Johnson | 27.5% decrease in revenue from OTC/Nutritionals in the US | Recall was issued in 1982 |
| Atrorvastatin[22] | Statin-type cholesterol-lowering drug | Ranbaxy | Analysts had projected $2.9 billion in sales within 4 years | 2012 |
| Mifepristone (Posicor) PPA | Used to treat high blood pressure or chest pain (angina) | Roche | Untold millions, if not billions (one manufacture alone settled for $15 million) | 1998 (after 1-year on the market) |
| Terfenadine (Seldane) | Used for everything from dieting to cold medication to treatment of psychological disorders | No principal manufacturer, widely manufactured across the industry | In addition to its legal expenses, the loss of market share alone to drugs such as Loratadine (Claritin) was steep | 2000 (at least 60 years on the market) |
| Troglitazone (Rezulin) | Antidiabetic and antiinflammatory drug | Hoechst Marion | In addition to its legal expenses, the loss of market share alone to drugs such as Lortanidine (Claritin) was steep | 1997, after 13 years on the market |
| Valdecoxib | Antiarthritis and pain from other inflammatory disorders | Roussel, now Aventis | To drugs such as Loratadine (Claritin) was steep | 2007 (after 13 years on the market) |
| Rofecoxib (Vioxx) | Antiarthritis and pain from other inflammatory disorders | Pfizer | Warner — Lambert grossed $2.1 billion in sales before recall | 2001 (after 4 years on the market) |
| Cervastatin (Baycol) DES | Treatment for high cholesterol | Merck | Nearly $6 billion in litigation-related expenses alone | 2005 (after just 1-year on the market) |
| Fenfluramine/ phentermine | To prevent miscarriages and other complications during pregnancy | Bayer | Litigation-related damages | 2004 (after 5 years on the market) |

Source: The data is collected from: http://xfinity.comcast.net/slideshow/finance-worstdrugrecalls/cerivastatin-baycol/, http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor/. PPA: Phenylpropanolamine, DES: Diethylstilbestrol, OTC: Over-the-counter.
Nevertheless the company’s best efforts to design manufacture and sell safe and authentic products, the possibility still exists that dangerously defective products may reach the consumer. A recall is an expensive undertaking even where patient safety is not at stake, not only in apparent costs, but also disservice to the reputation and the risk of litigation [Table 2]. It should be intone that the reason cited in a recall report may not reflect the root cause of an event, as establishing this generally requires the manufacturer to fetch an investigation into the incident to a close.[13] A number of factors can result in a drug to be recalled [Table 3].[14,15] A recall may be issued if a medicine:

- Cause health hazard
- Is mislabeled or packaged poorly
- Is potentially contaminated
- Is not what it says
- Is poorly manufactured

**ENFORCEMENT REPORT OF 2013 BY FOOD AND DRUG ADMINISTRATION**

According to the FDA enforcement report of 2012 in the fourth quarter, there were total 81 drug and pharmaceutical recalls.[16] Out of 81 recalls, four recalls were over-the-counter (OTC) products and seventy seven affected prescription medications. The FDA enforcement report of 2013 in the first quarter reveled that there were total 107 drug and pharmaceutical recalls.[17] The figure has increased by 32% as compared with the previous quarter and is higher than the average number of events of last year that is, 2012. The second quarter of 2013 showed 241 drug and pharmaceutical recalls according to FDA enforcement report. An increase of 127% from the previous quarter was observed in the second quarter. The FDA enforcement reported 171 drug and pharmaceutical recalls in the third quarter of the year 2013. In the third quarter, there was a decrease of 29% as compared with the previous quarter. Nationwide recalls in the fourth quarter were total 52 drug and pharmaceutical recalls, as documented in FDA enforcement reports [Figure 1 and Table 4].[18]

Chart is representing quarterly data of drug recalls. X-axis represents quarters of year and Y-axis represents the number of recalls.

**DENOTATIONS TO AVERT PRODUCT RECALL**

The drug recall leaves worst impression on pharmaceutical company’s financial situation.[19,20] Apart from that, market image of that company also suffers. There are certain contentions to subdue drug recall. The management system to overcome the drug recall involves:

- Ensuring compliance with industry and government regulations and standards
- Reducing risk of customer exposure by improving on time action

**Table 3: Cause of drug recall**

| Category                              | Example                                                                 |
|---------------------------------------|-------------------------------------------------------------------------|
| Manufacturing affined drug recall     | Marketed without an approved NDA/ANDA                                   |
| Safety/efficacy affined drug recall    | Super potent drug                                                          |
| Chemical contamination                 | Super potent drug                                                          |
| Failed impurities/degradation         | Microbial contamination of nonsterile products                           |
| specifications                        | Adverse drug reaction(s)                                                  |
| Defective container                   | Presence of particulate matter                                           |
| Nonstereity                           | CGMP deviation                                                           |
| Labeling: Label error on declared     | Failed dissolution specifications                                         |
| strength                              | Failed stability testing                                                  |
|                                       | Failed content uniformity specifications                                 |

CGMP: Current good manufacturing practice, NDA: New drug application, ANDAs: Abbreviated new drug applications

**Table 4: Quarterly data of drug recall**

| Drug recall class | Number of recalls |
|-------------------|-------------------|
| 2012 fourth quarter | 10  |
| Class I           | 10  |
| Class II          | 51  |
| Class III         | 20  |
| 2013 first quarter | 14  |
| Class I           | 14  |
| Class II          | 62  |
| Class III         | 31  |
| 2013 second quarter | 22  |
| Class I           | 22  |
| Class II          | 175 |
| Class III         | 44  |
| 2013 third quarter | 16  |
| Class I           | 16  |
| Class II          | 124 |
| Class III         | 31  |
| 2013 fourth quarter | 13  |
| Class I           | 13  |
| Class II          | 16  |
| Class III         | 23  |
The risk management program can work as an aid to anticipate the reasons for recall. The risk can be managed by using three strategies.\textsuperscript{[21]}

**Reducing risk**
During the initial phase of drug development and manufacturing, there should be a strict quality control measures to prevent recall. To handle a recall, crisis-management procedure should exist.

**Assuming risk**
Laying down all the possibilities due to which a recall can occur is another strategy to predict and resolve the recall issue.

**Transferring risk**
The third party, who could be a supplier or insurer, who is capable of share risk and to pay for the costs of drug recall, could help to overcome recall loss.

**CONCLUSION**
There has been an increasing trend in the number of prescribed and OTC drug recall over the last few years. The recall is usually due to company’s discovery, customer’s complaint or FDA observation.\textsuperscript{[18]} The critical recall information list includes the identity of the product; summary of the failure; amount of product produced in the distribution chain and direct account. Drug recall is incubus for pharmaceutical companies as it affects the reputation of the company. The most common reason that account for product recall is manufacturing affined. This inference that the production sequel didn’t followed the current Good Manufacturing Practice guidelines. Another reason involve safety/efficacy affined which suggest that the safety data was not appropriate, or some kind of biasing was involved during drug development time. It is essential to launch the drug in the market after assuring the safety and efficacy of the new intervention so as to minimize product recall. Major drug recall list of the history suggest that lots of carelessness is involved during the drug development and manufacturing period. The long list of drug recall on FDA website is evidence that still industries are not following the standard guidelines issued by FDA. The process of recall execution is followed by FDA and firms in very efficient manner. This execution step is effective enough to protect consumer’s health from a particular drug that requires recall. Therefore, even after launch of the drug in the market, it is essential to carry out postmarket surveillance and investigate the drug performance in the market.

**REFERENCES**

1. Fda.gov [Drugs/Drugsafety/DrugRecalls/default.htm]. U.S. Department of Health & Human Services. Available from: http://www.fda.gov/Drugs/Drugsafety/DrugRecalls/default.htm. [Last updated on 2014 Feb 18; Last accessed on 2014 Feb 21].

2. Sovasian N, Thacker S, Patel T. Quality management of complaints and recalls of pharmaceuticals as per global GMPs. Bihani S.D. College of Technical Education, Institute of Pharmaceutical Science & Drug Research, Sri Ganganagar, Rajasthan, India, Pharmacy Infopedia. Reference ID: PHARMATUTOR-ART-1258. Available from: http://www.pharmatutor.org/articles/quality-management-of-complaints-and-recall-of-pharmaceuticals-asper-global-gmp. [Last accessed on 2014 Feb 21].

3. Hsc.unm.edu. Pharmacistsletter, preceptor-training & resource network pharmacy 101, drug recalls and market withdrawals, preceptor key. Available from: http://www.hsc.unm.edu/pharmacy/docs/Pharmacy101forIPP&preceptorkey.pdf. [Last accessed on 2014 Feb 21].

4. Regulatory Procedure Manual. Recall Procedure. Ch. 7, October, 2013. Available from: http://www.webmd.boots.com/medications/guide/drug-recalls-what-are-they. [Last accessed on 2014 Feb 22].

5. WebMD Boots — Partners in health: Drug recalls; what are they? WebMD UK Limited and Boots UK Limited. Medically Reviewed by Dr. Rob Hicks on 2013, Nov 28. Available from: http://www.fda.gov/safety/recalls/ucm165546.htm. [Last accessed on 2014 Fw2].

6. Fda.gov [safety/recalls/ucm]. U.S. Department of Health & Human Services. Available from: http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm177309.htm. [Last updated on 2009 Jun 24; Last accessed on 2014 Feb 22].

7. Fda.gov [ICECI/ComplianceManuals/RegulatoryProcedures Manual]. U.S. Department of Health & Services. Available from: http://www.healthlawyers.org/ Members/PracticeGroups/LS/Documents/Oflaherty_all.pdf. [Last updated on 2014 Jan 31; Last accessed on 2014 Feb 22].

8. Lietzan E. Recalls of human drugs and medical devices. Available from: http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm. [Last accessed on 2014 Feb 22].

9. Fda.gov [safety/recalls/ucm]. U.S. Department of Health & Human Services. Available from: http://www.pharmatutor.org/articles/quality-management-of-complaints-and-recall-of-pharmaceuticals-as-per-global-gmp?page=0.2. [Last updated on 2012 Sep 19; Last accessed on 2014 Feb 22].

10. Xfinity.comcast.net [slideshow/finance/wordcountrecalls]. Available from: http://www.xfinity.comcast.net/slideshow/finance-worstdrugrecalls/cerivastatin-baycol/. [Last accessed on 2014 Feb 22].

11. CNNMoney Fortune [2013/05/15/Ranbaxy-fraud-lipitor]. Available from: http://www.features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor/. [Last updated on 2013 May15; Last accessed on 2014 Feb 22].

12. Pharmfile.com [news/154314/top-5-reasons-class-i-product-recall]. Available from: http://www.pharmfile.com/news/154814/top-5-reasons-class-i-product-recall. [Last updated on 2011 Apr 04; Last accessed on 2014 Feb 22].
13. Webmd.com [a-to-z-guide/what-is-a-drug-recall]. Reviewed by Ratini M. Available from: http://www.webmd.com/a-to-z-guides/what-is-a-drug-recall. [Last updated on 2013 Mar 19; Last accessed on 2014 Feb 22].

14. Fda.gov [Safety/Recalls/Enforcementreports/Default.htm.]. U.S. Department of Health & Human Services. Available from: http://www.fda.gov/safety/recalls/enforcementreports/default.htm. [Last updated on 2014 Mar 19; Last accessed on 2014 Feb 22].

15. ExpertRECALL™. An expert solution of stericycle; quarterly recall index. Available from: http://www.image.s4.exct.net/lib/fe9615707062027d72/m/1/2013+Q3+ExpertRECALL+Index.pdf. [Last accessed on 2014 Feb 22].

16. ExpertRECALL™. An expert solution of stericycle; quarterly recall index. Available from: http://www.recall.stericycleexpertsolutions.com/wp-content/uploads/sites/2/2013/10/Q4-2012_ExpertRECALL-index.pdf. [Last accessed on 2014 Feb 22].

17. Fda.gov [Safety/Recalls/EnforcementReports/2013]. U.S. Department of Health & Human Services. Available from: http://www.fda.gov/Safety/Recalls/EnforcementReports/2013/default.htm. [Last updated 2014 Feb 10; Last accessed on 2014 Feb 23].

18. Cafmeyer N, Lewis JM. How to effectively manage a product recall. Vol. 35, Issue 1. PharmTech.com. Available from: http://www.pharmtech.com/pharmtech/Ingredients/How-to-Effectively-Manage-a-Product-Recall/ArticleStandard/Article/detail/701939. [Last updated on 2011 Jan 02; Last accessed on 2014 Feb 23].

19. Chen Y, Shankar G, Liu Y. Does a firm's product-recall strategy affect its financial value? An examination of strategic alternatives during product-harm crises. J Mark 2009;73:214-26.

20. Hua X. Product recall and liability. J Law Econ Organ 2009;27:113-36. Available from: http://www.jleo.oxfordjournals.org/content/27/1/113.short.

21. Capturing recall costs, measuring and recovering the losses: Ernst & Young. Available from: http://www.ey.com/Publication/vwLUAssets/Capturing_Recall_Costs/$FILE/Capturing_recall_costs.pdf. [Last updated on 2011 Oct 5; Last accessed on 2014 Feb 23].

How to cite this article: Nagaich U, Sadhna D. Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history. Int J Pharma Investig 2015;5:13-9.

Source of Support: Nil. Conflict of Interest: None declared.